|Day Low/High||3.89 / 4.08|
|52 Wk Low/High||3.49 / 46.40|
-- IGNITE study showed Contrave combined with a commercially-available weight loss program yielded nearly 10 percent body weight loss that persisted for 78 weeks --
Campaign Aims to Showcase Attributes and Benefits of FDA-approved CONTRAVE®
Here's a technical look at how to trade several under-$10 stocks that are poised for breakouts.
These under -$10 stocks are poised to breakout and trade higher from current levels.
Orexigen has shipped the first order of Contrave tablets to partner Kwang Dong in anticipation of a commercial launch later this quarter
Acquisition magnifies projected long-term corporate profitability and opens multiple paths for shareholder value creation
Acquisition provides Orexigen ownership of CONTRAVE in nearly all major global markets
Orexigen Therapeutics (OREX) stock is falling on Friday morning after the company posted its 2015 fourth quarter results before today’s market open.
Investors in Orexigen Therapeutics, Inc. saw new options become available this week, for the October 21st expiration.
These stocks trading for less than $10 a share are within range of triggering big breakouts.
The most recent short interest data has been released by the NASDAQ for the 12/31/2015 settlement date, which shows a 13,255,786 share decrease in total short interest for Orexigen Therapeutics, Inc. , to 25,834,405, a decrease of 33.91% since 12/15/2015.
- Focus is managing to profitability by year end 2018